Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($1.00), $0.06 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $38.01 million versus the consensus estimate of $30.91 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.